Raseglurant
 | |
| Clinical data | |
|---|---|
| ATC code | None |
| Identifiers | |
| |
| CAS Number | 757950-09-7 |
| PubChem (CID) | 10331863 |
| ChemSpider | 8507323 |
| Chemical and physical data | |
| Formula | C15H13FN2 |
| Molar mass | 240.276 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Raseglurant (INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety.[1][2] It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.[2][3][4]
See also
References
- ↑ Annual Reports in Medicinal Chemistry. Academic Press. 31 December 2012. pp. 80–. ISBN 978-0-12-397214-9.
- 1 2 Murray B. Stein; Thomas Steckler (30 July 2010). Behavioral Neurobiology of Anxiety and Its Treatment. Springer Science & Business Media. pp. 397–. ISBN 978-3-642-02912-7.
- ↑ Celia Dominguez (18 November 2010). Neurodegenerative Diseases. Springer Science & Business Media. pp. 120–. ISBN 978-3-642-16758-4.
- ↑ Nicholas J. Shaheen (25 March 2013). Benign and Neoplastic Conditions of the Esophagus, An Issue of Gastroenterology Clinics,. Elsevier Health Sciences. pp. 119–. ISBN 1-4557-7175-9.
External links
This article is issued from Wikipedia - version of the 10/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.